Asieris Pharmaceuticals Announces Strategic Partnership with UroViu
Thursday, May 18, 2023
Asieris Pharmaceuticals announced a strategic collaboration with UroViu Corporation to further develop integrated diagnosis and treatment platform for bladder cancer.
Under the agreement, Asieris Pharmaceuticals will use this patented technology in combination with specific optical imaging agents to conduct research on the application of non-white light imaging technology in the diagnosis and postoperative monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC). At the same time, Asieris Pharmaceuticals will be responsible for the global commercialisation of the sterile single-use fluorescent Cystoscope.
This expanded collaboration with UroViu, enables not only to broaden technology portfolio, but also to expedite the implementation of Asieris’ integrated strategy for bladder cancer diagnosis and treatment, aiming to provide more effective disease management options for bladder cancer patients.
This unique and expanding portfolio of single use endoscopic products will fulfill UroViu’s promise to greatly improve both the patient and provider experience, and elevate the standard of care in a field with rapidly advancing technologies.
